The distinct mechanisms of action of isalpinin, characterized by PI3K/Akt pathway inhibition and reactive oxygen species-driven apoptosis, position it as a promising combinatorial agent, potentially facilitating reduced cisplatin dosages, thereby diminishing nephrotoxicity while preserving efficacy, and could act in concert with chemotherapeutic drugs within the tumor microenvironment. This evidence concerns the gene AKT1 and neoplasm.